Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis

被引：0
|
作者：
C. McArthur
C. Daruwalla
M. Jayeskara
J. W. L. Brown
机构：
[1] University of East Anglia,Norwich Medical School
[2] University of Cambridge,Department of Clinical Neurosciences
来源：
Journal of Neurology | 2023年 / 270卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5127 / 5129
页数：2
相关论文
共 50 条
  • [31] Real-world demographics, clinical characteristics and treatment patterns in relapsing multiple sclerosis patients on disease-modifying therapy
    Ziemssen, T.
    Kurzeja, A.
    Haas, J.
    Alexander, J.
    Driessen, M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 547 - 548
  • [32] Real-world Effectiveness Of Initial Treatment With Newer Versus Injectable Disease-modifying Therapies In Pediatric Multiple Sclerosis
    Krysko, K. M.
    Graves, J. S.
    Rensel, M.
    Weinstock-Guttman, B.
    Rutatangwa, A.
    Aaen, G.
    Anita, B.
    Benson, L.
    Chitnis, T.
    Gorman, M.
    Goyal, M. S.
    Harris, Y.
    Krupp, L.
    Lotze, T.
    Mar, S.
    Moodley, M.
    Ness, J.
    Rodriguez, M.
    Rose, J.
    Schreiner, T.
    Tillema, J.
    Waltz, M.
    Casper, T.
    Waubant, E.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 46 - 47
  • [33] Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis
    Hersh, Carrie M.
    Gorritz, Magdaliz
    Chen, Chi-Chang
    Tuly, Rifat
    Gu, Yifan
    Gadkari, Abhijit
    Brown, Brandon
    Shao, Qiujun
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 91
  • [34] Real-world Effectiveness of Initial Treatment with Newer versus Injectable Disease-modifying Therapies in Pediatric Multiple Sclerosis
    Krysko, Kristen
    Graves, Jennifer
    Rensel, Mary
    Weinstock-Guttman, Bianca
    Rutatangwa, Alice
    Aaen, Gregory
    Belman, Anita
    Benson, Leslie
    Chitnis, Tanuja
    Gorman, Mark
    Goyal, Manu
    Harris, Yolanda
    Krupp, Lauren
    Lotze, Timothy
    Mar, Soe
    Moodley, Manikum
    Ness, Jayne
    Rodriguez, Moses
    Rose, John
    Schreiner, Teri
    Tillema, Jan-Mendelt
    Waltz, Michael
    Casper, T. Charles
    Waubant, Emmanuelle
    NEUROLOGY, 2020, 94 (15)
  • [35] Characteristics of a population exposed to a disease-modifying drug for multiple sclerosis in the real-world setting (1996-2017)
    Ng, H. S.
    Zhu, F.
    Kingwell, E.
    Zhao, Y.
    Evans, C.
    Svenson, L.
    Fisk, J.
    Marrie, R. A.
    Tremlett, H.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 330 - 331
  • [36] Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis
    Thompson, Joel P.
    Abdolahi, Amir
    Noyes, Katia
    PHARMACOECONOMICS, 2013, 31 (06) : 455 - 469
  • [37] Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
    Morillo Verdugo, Ramon
    Ramirez Herraiz, Esther
    Fernandez-Del Olmo, Raquel
    Roig Bonet, Montserrat
    Valdivia Garcia, Maria
    PATIENT PREFERENCE AND ADHERENCE, 2019, 13 : 261 - 272
  • [38] Disease-modifying treatments for multiple sclerosis - a review of approved medications
    Torkildsen, O.
    Myhr, K. -M.
    Bo, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 18 - 27
  • [39] Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies
    Alvarez, Enrique
    Nair, Kavita V.
    Tan, Hiangkiat
    Rathi, Kapil
    Gabler, Nicole B.
    Maiese, Eric M.
    Deshpande, Chinmay
    Shao, Qiujun
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 494 - 502
  • [40] Prescribing disease-modifying treatments for older patients with multiple sclerosis
    Lopez Ruiz, Rocio
    Eichau Madueno, Sara
    Cortes Zujar, Beatriz
    Canaveral, Marta
    Arzalluz, Joaquin
    Ben Yelun Insenser, Miriam
    Dotor, Julio
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1086 - 1086
12345